[go: up one dir, main page]

AU2002239262A1 - Compositions of peptide crystals - Google Patents

Compositions of peptide crystals

Info

Publication number
AU2002239262A1
AU2002239262A1 AU2002239262A AU3926202A AU2002239262A1 AU 2002239262 A1 AU2002239262 A1 AU 2002239262A1 AU 2002239262 A AU2002239262 A AU 2002239262A AU 3926202 A AU3926202 A AU 3926202A AU 2002239262 A1 AU2002239262 A1 AU 2002239262A1
Authority
AU
Australia
Prior art keywords
compositions
peptide crystals
crystals
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002239262A
Inventor
Steven Witt Dodd
Rohn Lee Millican Jr.
Joseph Vincent Junior Rinella
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2002239262A1 publication Critical patent/AU2002239262A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Materials Engineering (AREA)
  • Endocrinology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Metallurgy (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2002239262A 2000-12-13 2001-12-06 Compositions of peptide crystals Abandoned AU2002239262A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25525100P 2000-12-13 2000-12-13
US60/255,251 2000-12-13
PCT/US2001/043183 WO2002048183A2 (en) 2000-12-13 2001-12-06 Compositions of peptide crystals

Publications (1)

Publication Number Publication Date
AU2002239262A1 true AU2002239262A1 (en) 2002-06-24

Family

ID=22967502

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2002228608A Abandoned AU2002228608A1 (en) 2000-12-13 2001-11-30 Amidated glucagon-like peptide-1
AU2002233929A Abandoned AU2002233929A1 (en) 2000-12-13 2001-12-06 Compositions of peptide crystals
AU2002239262A Abandoned AU2002239262A1 (en) 2000-12-13 2001-12-06 Compositions of peptide crystals

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AU2002228608A Abandoned AU2002228608A1 (en) 2000-12-13 2001-11-30 Amidated glucagon-like peptide-1
AU2002233929A Abandoned AU2002233929A1 (en) 2000-12-13 2001-12-06 Compositions of peptide crystals

Country Status (4)

Country Link
US (1) US7199217B2 (en)
EP (1) EP1351984A2 (en)
AU (3) AU2002228608A1 (en)
WO (3) WO2002048192A2 (en)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (en) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
CA2405709A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
EP2186824A3 (en) 2000-12-13 2010-09-22 Eli Lilly & Company Chronic treatment regimen using glucagon-like insulinotropic peptides
DE60224284T2 (en) 2001-06-28 2008-12-18 Novo Nordisk A/S STABLE FORMULATION OF MODIFIED GLP-1
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
ES2545090T3 (en) 2001-12-21 2015-09-08 Human Genome Sciences, Inc. Albumin and GCSF fusion proteins
AU2003219922B2 (en) * 2002-02-27 2009-09-10 Pharmain Corporation Compositions for delivery of therapeutics and other materials, and methods of making and using the same
US20050260259A1 (en) * 2004-04-23 2005-11-24 Bolotin Elijah M Compositions for treatment with glucagon-like peptide, and methods of making and using the same
US7635463B2 (en) * 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
US7790681B2 (en) 2002-12-17 2010-09-07 Amylin Pharmaceuticals, Inc. Treatment of cardiac arrhythmias with GLP-1 receptor ligands
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
EP1631308B1 (en) 2003-05-30 2013-07-31 Amylin Pharmaceuticals, LLC Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins
CN102940879B (en) * 2003-06-03 2017-06-06 诺沃挪第克公司 Stabilized pharmaceutical peptide compositions
WO2004105790A1 (en) 2003-06-03 2004-12-09 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
WO2004105781A2 (en) * 2003-06-03 2004-12-09 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
EP1663295A2 (en) * 2003-09-01 2006-06-07 Novo Nordisk A/S Stable formulations of peptides
PL1687019T3 (en) 2003-11-20 2018-05-30 Novo Nordisk A/S Peptide formulations containing propylene glycol that are optimal for production and for use in injection devices
ES2442223T3 (en) 2004-08-31 2014-02-10 Novo Nordisk A/S Use of tris (hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins
EP1817048B1 (en) 2004-11-12 2014-02-12 Novo Nordisk A/S Stable formulations of insulinoptropic peptides
WO2006069779A1 (en) * 2004-12-30 2006-07-06 F. Hoffmann-La Roche Ag Preparing of peptides with excellent solubility
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US8052996B2 (en) 2005-02-03 2011-11-08 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
NZ565535A (en) 2005-06-30 2011-03-31 Ipsen Pharma Sas GLP-1 pharmaceutical compositions
CN101534846B (en) 2005-11-07 2014-11-05 印第安纳大学研究及科技有限公司 Glucagon analogs exhibiting physiological solubility and stability
CN100374462C (en) * 2005-11-21 2008-03-12 大连帝恩生物工程有限公司 Truncated glucagon-like peptide 1 (sGLP-1), preparation method and application
EP3449946A3 (en) 2005-12-19 2020-11-04 PharmaIN Corporation Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
EP2574624A1 (en) 2006-04-20 2013-04-03 Amgen Inc. GLP-1 compounds
PT2359808E (en) 2006-08-09 2013-08-28 Intarcia Therapeutics Inc Osmotic delivery systems and piston assemblies
US20120214965A1 (en) * 2011-02-23 2012-08-23 Elona Biotechnologies Glargine proinsulin and methods of producing glargine insulin analogs therefrom
US10100098B2 (en) 2006-12-13 2018-10-16 Stelis Biopharma Private Limited Insulin production methods and proinsulin constructs
ES2628063T3 (en) 2007-01-05 2017-08-01 Indiana University Research And Technology Corporation Glucagon analogs showing greater solubility in physiological pH buffers
CA2677932A1 (en) 2007-02-15 2008-08-21 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
PL2157967T3 (en) 2007-04-23 2013-06-28 Intarcia Therapeutics Inc Suspension formulations of insulinotropic peptides and uses thereof
US7960336B2 (en) * 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) * 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
WO2009058662A2 (en) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Glucagon antagonists
US8980830B2 (en) 2007-10-30 2015-03-17 Indiana University Research And Technology Corporation Peptide compounds exhibiting glucagon antagonist and GLP-1 agonist activity
US20090176892A1 (en) 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US8450270B2 (en) 2008-06-17 2013-05-28 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers
HUE028072T2 (en) 2008-06-17 2016-11-28 Univ Indiana Res & Tech Corp Gip-based mixed agonists for treatment of metabolic disorders and obesity
MX2010013454A (en) 2008-06-17 2011-01-21 Tion Indiana University Res And Technology Corpora Glucagon/glp-1 receptor co-agonists.
KR20110110174A (en) 2008-12-19 2011-10-06 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Amide-based Glucagon Superfamily Peptide Prodrugs
IN2012DN00377A (en) 2009-06-16 2015-08-21 Univ Indiana Res & Tech Corp
HUE035862T2 (en) 2009-09-28 2018-05-28 Intarcia Therapeutics Inc Rapid development and / or completion of substantially steady-state drug delivery
US20110097386A1 (en) * 2009-10-22 2011-04-28 Biodel, Inc. Stabilized glucagon solutions
WO2011067283A1 (en) 2009-12-01 2011-06-09 Novo Nordisk A/S Novel peptidyl alpha-hydroxyglycine alpha-amidating lyases
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
JP2013518115A (en) 2010-01-27 2013-05-20 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity
SG183993A1 (en) * 2010-03-09 2012-10-30 Alkermes Pharma Ireland Ltd Alcohol resistant enteric pharmaceutical compositions
JP6050746B2 (en) 2010-05-13 2016-12-21 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation Glucagon superfamily of peptides exhibiting G protein-coupled receptor activity
ES2661228T3 (en) 2010-05-13 2018-03-28 Indiana University Research And Technology Corporation Glucagon superfamily peptides that show nuclear hormone receptor activity
KR20130102470A (en) 2010-06-24 2013-09-17 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Amide based glucagon superfamily peptide prodrugs
EP3326620B1 (en) 2010-12-16 2020-03-04 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2- hydroxybenzoyl)amino)caprylic acid
KR20130132931A (en) 2010-12-22 2013-12-05 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Glucagon analogs exhibiting gip receptor activity
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN106117344B (en) 2011-04-12 2020-11-03 诺沃—诺迪斯克有限公司 Diacylated GLP-1 Derivatives
US8729017B2 (en) 2011-06-22 2014-05-20 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
LT2723367T (en) 2011-06-22 2017-08-25 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
KR20140097151A (en) 2011-11-17 2014-08-06 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
ES2715308T3 (en) 2012-03-22 2019-06-03 Novo Nordisk As Compositions comprising a supply agent and its preparation
CN104203266B (en) 2012-03-22 2017-12-26 诺和诺德股份有限公司 The peptide combinations of GLP 1 and its preparation
WO2013170636A1 (en) 2012-05-18 2013-11-21 爱德迪安（北京）生物技术有限公司 Protein and protein conjugate for diabetes treatment, and applications thereof
WO2013189988A1 (en) 2012-06-20 2013-12-27 Novo Nordisk A/S Tablet formulation comprising a peptide and a delivery agent
TWI599575B (en) 2012-06-21 2017-09-21 印第安納大學科技研究公司 Glucagon analogs exhibiting gip receptor activity
SI2991671T1 (en) 2013-05-02 2018-10-30 Novo Nordisk A/S Oral dosing of glp-1 compounds
EP3077008B1 (en) 2013-12-06 2023-10-04 Jie Han Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
MX2017015504A (en) 2015-06-03 2018-05-15 Intarcia Therapeutics Inc Implant placement and removal systems.
CA3024479A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
CN110225762A (en) 2017-01-03 2019-09-10 因塔西亚制药公司 The method of the co-administration of continuous administration and drug including GLP-1 receptor stimulating agent
CN118903385A (en) 2017-08-24 2024-11-08 诺和诺德股份有限公司 GLP-1 compositions and uses thereof
JP6898518B2 (en) 2018-02-02 2021-07-07 ノヴォ ノルディスク アー／エス A solid composition comprising a GLP-1 agonist, a salt of N- (8- (2-hydroxybenzoyl) amino) caprylic acid and a lubricant.
CA3116023A1 (en) 2018-10-11 2020-04-16 Intarcia Therapeutics, Inc. Human amylin analog polypeptides and methods of use
PE20230819A1 (en) 2020-02-18 2023-05-19 Novo Nordisk As COMPOSITIONS AND USES OF GLP-1

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4347374A (en) * 1980-07-21 1982-08-31 Merck & Co., Inc. Acid addition salts of N-trityl-α-fluoromethylhistidine enantiomer derivatives
US5120712A (en) * 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
EP0305387B2 (en) 1986-05-05 1996-08-28 The General Hospital Corporation Insulinotropic hormone
US5118666A (en) * 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
DE69129226T2 (en) 1990-01-24 1998-07-30 Douglas I. Woodside Calif. Buckley GLP-1 ANALOG USES IN DIABETE TREATMENT
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
WO1992018531A1 (en) 1991-04-09 1992-10-29 F. Hoffmann-La Roche Ag Growth hormone releasing factor analogs
DK36392D0 (en) 1992-03-19 1992-03-19 Novo Nordisk As USE OF CHEMICAL COMPOUND
KR0154880B1 (en) 1992-06-15 1998-10-15 피터 알.셰어러 Glucagon-like peptides and insulinotropin derivatives
HU225496B1 (en) 1993-04-07 2007-01-29 Scios Inc Pharmaceutical compositions of prolonged delivery, containing peptides
US6284727B1 (en) * 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
WO1995005848A1 (en) 1993-08-24 1995-03-02 Novo Nordisk A/S Protracted glp-1
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
ES2273501T3 (en) * 1998-06-30 2007-05-01 Novo Nordisk A/S GERMINATION CRYSTALS FOR THE PREPARATION OF PEPTIDES OR PROTEINS.
AU2001228327A1 (en) * 2000-01-31 2001-08-14 Novo-Nordisk A/S Crystallisation of a glp-1 analogue
JP2004509079A (en) 2000-08-02 2004-03-25 セラテクノロジーズ・インコーポレーテッド Modified biological peptides with increased potency
WO2002046227A2 (en) * 2000-12-07 2002-06-13 Eli Lilly And Company Glp-1 fusion proteins

Also Published As

Publication number Publication date
WO2002048192A2 (en) 2002-06-20
US20040132647A1 (en) 2004-07-08
WO2002048183A3 (en) 2003-06-05
WO2002047715A2 (en) 2002-06-20
EP1351984A2 (en) 2003-10-15
AU2002233929A1 (en) 2002-06-24
WO2002048192A3 (en) 2003-08-07
WO2002048183A2 (en) 2002-06-20
US7199217B2 (en) 2007-04-03
AU2002228608A1 (en) 2002-06-24
WO2002047715A3 (en) 2003-01-30

Similar Documents

Publication Publication Date Title
AU2002233929A1 (en) Compositions of peptide crystals
AU4133701A (en) Methods and compositions for peptide synthesis
AU2001286233A1 (en) Cement composition
AU2002219418A1 (en) Compositions of estrogen-cyclodextrin complexes
AU2001234105A1 (en) Cement composition
AU7719100A (en) Compositions of tocol-soluble therapeutics
AU2001233691A1 (en) Antiperspirant compositions
AU2001233081A1 (en) Composition for treatment of stress
AU2002330453A1 (en) Crystals of hydroxynorephedrine derivative
AU2001245764A1 (en) Novel compounds and compositions as protease inhibitors
AU2001285790A1 (en) Antiperspirant compositions
AU2002338709A1 (en) Workability-improving agents for cement compositions
AU2001244692A1 (en) Novel crystal form of pyrrolidylthiocarbapenem derivative
AU2002217071A1 (en) Novel use of polyhydroxy compounds
EP1407780A4 (en) Pharmaceutically stable hemostatic compositions
AU2001269685A1 (en) Crystallization of 4-diphosphocytidyl-2-c-methylerythritol synthesis
AU1287100A (en) Peptide inhibitor of browman-birk type
AU2001267522A1 (en) Cosmetic compositions containing substituted amide derivatives
AU2002246659A1 (en) Benzoylalkylindolepyridinium compounds and pharmaceutical compositions comprising such compounds
AU2002362579A1 (en) Tetrapeptide derivative crystals
AU2001296389A1 (en) Stable peptide formulations
AU2002246658A1 (en) Benzoylalkylindolepyridinium compounds and pharmaceutical compositions comprising such compounds
AU2001277750A1 (en) Use of polypeptide
AU2001286584A1 (en) Inhibition of protein-protein interaction
AU2001258330A1 (en) New uses of imidazolylmethyl-pyridines